Saturday, January 02, 2021 1:14:20 AM
Frost grew Opko on the backs of shareholders investments of which many got the crap squeezed out of them and lost alot. I watched it for years. He continues to show no interest in putting forth a game plan to promote any of the divisions of the companies highlights. When someone pike Sian actually does, from an investment return perspective and a humanitarian (rayaldee statistically may stop the insane ICU visits) aid, why is the company not embracing this? Wheres the PR showing action in working with congressional leaders or FDA to get rid of this ICU death rate? SAVE THE 1% for the sake of the other 99%!
Like Ive always said, when Frost gets %51 control, its game over, whether he lets investors in or not is yet to be seen.
Like Ive always said, when Frost gets %51 control, its game over, whether he lets investors in or not is yet to be seen.
Recent OPK News
- OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies • GlobeNewswire Inc. • 05/12/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/30/2026 08:04:06 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 08:01:43 PM
- OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China • GlobeNewswire Inc. • 04/30/2026 12:30:00 PM
- BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform • GlobeNewswire Inc. • 04/30/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 08:06:14 PM
- OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results • GlobeNewswire Inc. • 04/28/2026 08:05:00 PM
- OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas • GlobeNewswire Inc. • 04/22/2026 12:00:00 PM
- OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026 • GlobeNewswire Inc. • 04/21/2026 08:05:00 PM
- OPKO Health’s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19 • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 08:25:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 08:16:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2026 08:50:09 PM
- OPKO Health to Participate in the Jefferies Biotech on the Beach Summit • GlobeNewswire Inc. • 02/27/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 09:07:43 PM
- OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results • GlobeNewswire Inc. • 02/26/2026 09:05:00 PM
- OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26 • GlobeNewswire Inc. • 02/12/2026 01:00:00 PM
- OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism • GlobeNewswire Inc. • 02/04/2026 01:00:00 PM
- OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/06/2026 09:11:42 PM
- OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference • GlobeNewswire Inc. • 11/19/2025 09:05:00 PM
- NextPlat Reports Third Quarter 2025 Results • PR Newswire (US) • 11/13/2025 01:03:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/29/2025 08:12:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/29/2025 08:11:05 PM
- OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results • GlobeNewswire Inc. • 10/29/2025 08:05:00 PM
